FDA grants accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for metastatic colorectal cancer
Last updated: 01 November 2019
You can legally access new medicines, even if they are not approved in your country.
Learn more »
The FDA granted an accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.
Find out more about the approval in this Onclive article.